Literature DB >> 8484132

Hypogammaglobulinemia and rheumatic disease.

A H Lee1, A I Levinson, H R Schumacher.   

Abstract

Primary hypogammaglobulinemia describes a heterogeneous group of immunoglobulin disorders mainly composed of X-linked agammaglobulinemia, common variable immunodeficiency, and selective immunoglobulin (Ig) A deficiency. The most serious problems are related to recurrent infections with high-grade encapsulated bacteria. However, a wide variety of rheumatologic disorders also occur in association with hypogammaglobulinemic states. Septic arthritis with usual bacterial pathogens such as Staphylococcus aureus, and unusual bacteria such as Mycoplasma and Ureaplasma species, have been described in these patients. An aseptic nonerosive polyarticular arthritis that resembles rheumatoid arthritis is seen in 10% to 30% of hypogammaglobulinemic patients. Autoimmune disorders such as immune thrombocytopenic purpura, immune hemolytic anemia, juvenile rheumatoid arthritis, systemic lupus erythematosus, dermatomyositis, Sjögren's syndrome, essential mixed cryoglobulinemia, chronic active hepatitis, and sarcoidosis have been reported in hypogammaglobulinemic patients. Finally, to complicate matters, many disease-modifying antirheumatic drugs, including gold, D-penicillamine, sulfasalazine, azathioprine, and cyclophosphamide, cause symptomatic hypogammaglobulinemia in some patients.

Entities:  

Mesh:

Year:  1993        PMID: 8484132     DOI: 10.1016/0049-0172(93)80073-o

Source DB:  PubMed          Journal:  Semin Arthritis Rheum        ISSN: 0049-0172            Impact factor:   5.532


  24 in total

Review 1.  Balancing immunity and tolerance: deleting and tuning lymphocyte repertoires.

Authors:  C C Goodnow
Journal:  Proc Natl Acad Sci U S A       Date:  1996-03-19       Impact factor: 11.205

2.  Phenotypic characterization of patients with rheumatologic manifestations of common variable immunodeficiency.

Authors:  Maria J Gutierrez; Kathleen E Sullivan; Ramsay Fuleihan; Clifton O Bingham
Journal:  Semin Arthritis Rheum       Date:  2018-02-23       Impact factor: 5.532

3.  Subcutaneous Immunoglobulin for Antibody Deficiency in Antineutrophil Cytoplasmic Antibody (ANCA)-associated Vasculitis.

Authors:  Sam Kant; Antoine Azar; Eric J Gapud; Brendan Antiochos; Rebecca Manno; Philip Seo; Duvuru Geetha
Journal:  Cureus       Date:  2019-12-12

4.  Antibody deficiency associated with gold treatment: natural history and management in 22 patients.

Authors:  N Snowden; D M Dietch; L S Teh; R C Hilton; M R Haeney
Journal:  Ann Rheum Dis       Date:  1996-09       Impact factor: 19.103

5.  Common variable immunodeficiency.

Authors:  Jonathan S Tam; John M Routes
Journal:  Am J Rhinol Allergy       Date:  2013 Jul-Aug       Impact factor: 2.467

Review 6.  Rheumatologic and autoimmune manifestations of primary immunodeficiency disorders.

Authors:  Ramona Goyal; Ariel C Bulua; Nikolay P Nikolov; Pamela L Schwartzberg; Richard M Siegel
Journal:  Curr Opin Rheumatol       Date:  2009-01       Impact factor: 5.006

7.  Autoimmune manifestations in common variable immunodeficiency.

Authors:  Stavroula Giannouli; Dimitra Anagnostou; Fotini Soliotis; Michalis Voulgarelis
Journal:  Clin Rheumatol       Date:  2004-06-18       Impact factor: 2.980

8.  Acute respiratory failure in a patient with sarcoidosis and immunodeficiency--an unusual presentation and a complicated course.

Authors:  Adi Leiba; Sara Apter; Merav Leiba; Michael Thaler; Ehud Grossman
Journal:  Lung       Date:  2004       Impact factor: 2.584

Review 9.  Osteoarticular infectious complications in patients with primary immunodeficiencies.

Authors:  Katherine A Bloom; Danna Chung; Charlotte Cunningham-Rundles
Journal:  Curr Opin Rheumatol       Date:  2008-07       Impact factor: 5.006

Review 10.  Recognition, clinical diagnosis and management of patients with primary antibody deficiencies: a systematic review.

Authors:  P Wood; S Stanworth; J Burton; A Jones; D G Peckham; T Green; C Hyde; H Chapel
Journal:  Clin Exp Immunol       Date:  2007-06-12       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.